Get to know our clinical trials
Apixaban for the Reduction of Thromboembolism in Patients With Device-Detected Subclinical Atrial Fibrillation
THE PURPOSE OF THIS CLINICAL TRIAL IS TO DETERMINE WHICH TREATMENT IS BEST FOR PREVENTING STROKE OR SYSTEMIC EMBOLISM IN PATIENTS WHO HAVE EXPERIENCED AT LEAST ONE DEVICE-DETECTED EPISODE OF ATRIAL FIBRILLATION AND WHO ALSO HAVE OTHER RISK FACTORS FOR STROKE. THIS IS A SUMMARY OF THE CLINICAL TRIAL. ONCE YOU CONTACT US, WE WILL PROVIDE YOU WITH ALL THE INFORMATION YOU NEED.
- APIXABAN FOR THE REDUCTION OF THROMBOEMBOLISM IN PATIENTS WITH DEVICE-DETECTED SUBCLINICAL ATRIAL FIBRILLATION
- Code EudraCT: 2014-001397-33
- Protocol number: ARTESIA
- Promoter: Population Health Research Institute (PHRI)
- Molecule/Drug: Apixabán
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.